Upsher-Smith inks deal to distribute generic CNS product in USA
US drugmaker Upsher-Smith has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute a generic central nervous system (CNS) product with US sales of more than $200 million for the 12 months ending June 2016, according to IMS Health.
This collaboration is part of Upsher-Smith's company-wide effort to grow its generics pipeline and to expand its strategic relationships within the pharmaceutical industry.
Under the terms of the agreement, the unnamed partner will develop, manufacture and supply the product exclusively for Upsher-Smith, which will market and distribute the product under its own label in the USA. Financial terms related to the deal have not been disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze